BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 20061694)

  • 1. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients.
    Helal I; Smaoui W; Hamida FB; Ouniss M; Aderrahim E; Hedri H; Elyounsi F; Maiz HB; Abdallah TB; Kheder A
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):59-62. PubMed ID: 20061694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular risk assessment and homocysteine and leptin levels in peritoneal dialysis and hemodialysis patients.
    Bekpinar S; Unlüçerçi Y; Genç S; Türkmen A
    Adv Perit Dial; 2005; 21():80-4. PubMed ID: 16686291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of serum cystatin C with C-reactive protein and apolipoprotein A1 in patients on hemodialysis.
    Samouilidou EC; Grapsa E
    Ren Fail; 2008; 30(7):711-5. PubMed ID: 18704820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
    Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
    Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.
    Lobo J; Santos F; Grosso D; Lima R; Barreira AL; Leite M; Mafra D; Abdalla DS
    Nephron Clin Pract; 2008; 108(4):c298-304. PubMed ID: 18434752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease.
    Buccianti G; Baragetti I; Bamonti F; Furiani S; Dorighet V; Patrosso C
    J Nephrol; 2004; 17(3):405-10. PubMed ID: 15365961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD.
    Sjöberg B; Anderstam B; Suliman M; Alvestrand A
    Am J Kidney Dis; 2006 Jan; 47(1):60-71. PubMed ID: 16377386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atherogenic lipid profile and lipoprotein(a) in relation to serum albumin in haemodialysis patients.
    Yang WS; Kim SB; Min WK; Park S; Lee MS; Park JS
    Nephrol Dial Transplant; 1995; 10(9):1668-71. PubMed ID: 8559487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients.
    Afzali B; Bakri RS; Bharma-Ariza P; Lumb PJ; Dalton N; Turner NC; Wierzbicki AS; Crook MA; Goldsmith DJ
    J Nephrol; 2003; 16(4):540-5. PubMed ID: 14696756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-dialysis retention of blood lipoproteins and apolipoproteins in patients with end-stage renal disease on maintenance haemodialysis in Kuwait.
    Al-Rashidi M; Hussain AA; Nampoory MR; Al-Ali JH; Akanji AO
    Clin Chim Acta; 2004 Jun; 344(1-2):149-54. PubMed ID: 15149883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
    Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
    Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive correlation of CRP and fibrinogen levels as cardiovascular risk factors in early stage of continuous ambulatory peritoneal dialysis patients.
    Tekin IO; Pocan B; Borazan A; Ucar E; Kuvandik G; Ilikhan S; Demircan N; Ozer C; Kadayifci S
    Ren Fail; 2008; 30(2):219-25. PubMed ID: 18300125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
    Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
    Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of hemodialysis and peritoneal dialysis on serum homocysteine and C-reactive protein levels.
    Borazan A; Aydemir S; Sert M; Yilmaz A
    Mediators Inflamm; 2004 Dec; 13(5-6):361-4. PubMed ID: 15770053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body mass index and cardiovascular risk factors and biomarkers in hemodialysis patients.
    Bossola M; Giungi S; Panocchia N; Vulpio C; Luciani G; Tazza L
    J Nephrol; 2008; 21(2):197-204. PubMed ID: 18446714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between apolipoprotein E gene polymorphism and plasminogen activator inhibitor-1 and atherogenic lipid profile in dialysis patients.
    Arikan H; Koc M; Sari H; Tuglular S; Ozener C; Akoglu E
    Ren Fail; 2007; 29(6):713-9. PubMed ID: 17763167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients.
    Noordzij M; Korevaar JC; Bos WJ; Boeschoten EW; Dekker FW; Bossuyt PM; Krediet RT
    Nephrol Dial Transplant; 2006 Sep; 21(9):2513-20. PubMed ID: 16799173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dyslipidemia in patients being treated with peritoneal dialysis].
    Zharfbin A
    Vnitr Lek; 2006 Nov; 52(11):1051-7. PubMed ID: 17165524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malnutrition, inflammation, and lipids in a cohort of dialysis patients.
    Bowden RG; Wilson RL
    Postgrad Med; 2010 May; 122(3):196-202. PubMed ID: 20463430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for vascular complications in patients on peritoneal dialysis.
    Arima H; Nakamoto H; Okada S; Inoue T; Kobayashi K; Shoda J; Ikeda N; Kanno Y; Sugahara S; Okada H; Suzuki H
    Adv Perit Dial; 2006; 22():192-7. PubMed ID: 16983968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.